Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study

Show full item record



Permalink

http://hdl.handle.net/10138/211434

Citation

Dalgard , O , Weiland , O , Noraberg , G , Karlsen , L , Heggelund , L , Farkkila , M , Balslev , U , Belard , E , Ovrehus , A , Kjaer , M S , Krarup , H , Roge , B T , Hallager , S , Madsen , L G , Laursen , A L , Lagging , M & Weis , N 2017 , ' Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study ' , PLoS One , vol. 12 , no. 7 , e0179764 . https://doi.org/10.1371/journal.pone.0179764

Title: Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study
Author: Dalgard, Olav; Weiland, Ola; Noraberg, Geir; Karlsen, Lars; Heggelund, Lars; Farkkila, Martti; Balslev, Ulla; Belard, Erika; Ovrehus, Anne; Kjaer, Mette Skalshoi; Krarup, Henrik; Roge, Birgit Thorup; Hallager, Sofie; Madsen, Lone G.; Laursen, Alex Lund; Lagging, Martin; Weis, Nina
Contributor: University of Helsinki, Clinicum
Date: 2017-07-13
Language: eng
Number of pages: 8
Belongs to series: PLoS One
ISSN: 1932-6203
URI: http://hdl.handle.net/10138/211434
Abstract: Background and aims Chronic hepatitis C virus (HCV) genotype 3 infection with advanced liver disease has emerged as the most challenging to treat. We retrospectively assessed the treatment outcome of sofosbuvir (SOF) based regimes for treatment of HCV genotype 3 infections in a real life setting in Scandinavia. Methods Consecutive patients with chronic HCV genotype 3 infection were enrolled at 16 treatment centers in Denmark, Sweden, Norway and Finland. Patients who had received a SOF containing regimen were included. The fibrosis stage was evaluated by liver biopsy or transient liver elastography. The following treatments were given according availability and local guidelines: 1) SOF + ribavirin (RBV) for 24 weeks, 2) SOF + daclatasvir (DCV) +/-RBV for 12-24 weeks, 3) SOF + pegylated interferon alpha (peg-IFN-a) + RBV for 12 weeks or 4) SOF/ledipasvir (LDV) + RBV for 12-16 weeks. The primary endpoint was sustained virological response (SVR) assessed at week 12 (SVR12) after end of treatment. Results We included 316 patients with a mean age of 55 years (range 24-79), 70% men, 49% treatment experienced, 58% with compensated cirrhosis and 12% with decompensated cirrhosis. In the modified intention to treat (mITT) population SVR12 was achieved in 284/311 91%) patients. Among 26 treatment failures, five had non-response, 3 breakthrough and 18 relapse. Five patients were not included in the mITT population. Three patients died from reasons unrelated to treatment and two were lost to follow-up. The SVR12 rate was similar for all treatment regimens, but lower in men (p = 0.042), and in patients with decompensated liver disease (p = 0.004). Conclusion We found that sofosbuvir based treatment in a real-life setting could offer SVR rates exceeding 90% in patients with HCV genotype 3 infection and advanced liver disease.
Subject: ADVANCED LIVER-DISEASE
DECOMPENSATED CIRRHOSIS
PHASE-III
HCV
VIRUS
DACLATASVIR
RIBAVIRIN
EPIDEMIOLOGY
VELPATASVIR
LEDIPASVIR
3121 Internal medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
file.pdf 1.718Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record